ReviewThe American journal of tropical medicine and hygiene2011
Review: Malaria chemoprophylaxis for travelers to Latin America.
Review in The American journal of tropical medicine and hygiene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.The Cochrane database of systematic reviews · 2021Pooled it
- G6PD deficiency in Latin America: systematic review on prevalence and variants.Memorias do Instituto Oswaldo Cruz · 2014Pooled it
- Single loading-dose tafenoquine for malaria chemoprophylaxis during brief travel?Journal of travel medicine · 2021Article
- Tafenoquine for travelers' malaria: evidence, rationale and recommendations.Journal of travel medicine · 2018Article
- Pre-travel malaria chemoprophylaxis counselling in a public travel medicine clinic in São Paulo, Brazil.Malaria journal · 2017Article
- Recommendations for malaria prevention in moderate to low risk areas: travellers' choice and risk perception.Malaria journal · 2015Article
- Severe morbidity and mortality risk from malaria in the United States, 1985-2011.Open forum infectious diseases · 2014Article
- HLA class II (DR0401) molecules induce Foxp3+ regulatory T cell suppression of B cells in Plasmodium yoelii strain 17XNL malaria.Infection and immunity · 2014Article
- Malaria prophylaxis in Latin America: a controversial topic.The American journal of tropical medicine and hygiene · 2012Article
- An update on prevention of malaria in travelers.Therapeutic advances in infectious diseaseReview
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because of recent declining malaria transmission in Latin America, some authorities have recommended against chemoprophylaxis for most travelers to this region. However, the predominant parasite species in Latin America, Plasmodium vivax, can form hypnozoites sequestered in the liver, causing malaria relapses. Additionally, new evidence shows the potential severity of vivax infections, warranting continued consideration of prophylaxis for travel to Latin America. Individualized travel risk assessments are recommended and should consider travel locations, type, length, and season, as well as probability of itinerary changes. Travel recommendations might include no precautions, mosquito avoidance only, or mosquito avoidance and chemoprophylaxis. There are a range of good options for chemoprophylaxis in Latin America, including atovaquone-proguanil, doxycycline, mefloquine, and--in selected areas--chloroquine. Primaquine should be strongly considered for nonpregnant, G6PD-nondeficient patients traveling to vivax-endemic areas of Latin America, and it has the added benefit of being the only drug to protect against malaria relapses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.